Search

Displaying results 4841 - 4850 of 7602 in total
  1. Drug

    B27PD

    go.drugbank.com/drugs/DB16289
    Investigational

    B27PD is under investigation in clinical trial NCT01195948 (Optiquel® as Corticosteroid-sparing Therapy for Chronic Noninfectious Uveitis).

  2. Drug

    Vicagrel

    go.drugbank.com/drugs/DB16349
    Investigational

    Vicagrel is under investigation in clinical trial NCT03599284 (The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel).

  3. Drug

    2,4-thiazolidinedione

    go.drugbank.com/drugs/DB11898
    Investigational

    Thiazolidinedione has been investigated for the treatment of Type 2 Diabetes, Diabetes Mellitus, and DIABETES MELLITUS, TYPE 2.

  4. Drug

    Golvatinib

    go.drugbank.com/drugs/DB11977
    Investigational

    Golvatinib has been investigated for the treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck.

  5. Drug

    Avoplacel

    go.drugbank.com/drugs/DB18659
    Investigational

    Avoplacel (PLX-R18) is an allogeneic cell therapy under investigation for the treatment of acute radiation syndrome.[L48370]

  6. Drug

    Gamma cyclodextrin

    go.drugbank.com/drugs/DB19173
    Investigational

    Gamma cyclodextrin is under investigation in clinical trial NCT03931057 (The use of ADV6209 for Premedication in Pediatric Anesthesia).

  7. Drug

    Recaticimab

    go.drugbank.com/drugs/DB19302
    Investigational

    Recaticimab is under investigation in clinical trial NCT06467617 (Adebrelimab Plus Chemo and Recaticimab Perioperative Treatment for Resectable NSCLC).

  8. Drug

    COVID19 s-vax loaded autologous dendritic cell vaccine

    go.drugbank.com/drugs/DB15814
    Experimental

    DC-based vaccines are currently used in cancer therapeutics, and are being tested for COVID-19. … , and are able to present antigens through costimulatory signals required for activation of CD4+ and CD8+ T-cells.

  9. Drug

    EVT 201

    go.drugbank.com/drugs/DB05721
    Investigational

    EVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being developed as a treatment for insomnia. It is being developed by Evotec Inc.

  10. Drug

    Influenza B virus B/Michigan/01/2021 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB16917
    Approved

    In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. … Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde.